Should I discontinue olmesartan (angiotensin II receptor blocker) because my eGFR has declined since I started it 10 months ago, and how should I manage my hypertension now?

Do Not Discontinue Olmesartan Based on eGFR Decline Alone

An expected decline in eGFR of up to 30% within 2-4 weeks after starting or titrating an ARB like olmesartan is a normal hemodynamic response, not kidney injury, and should not prompt discontinuation. This "dip" reflects efferent arteriolar vasodilation and is actually associated with long-term kidney protection 1, 2, 3, 4.

Understanding the Expected eGFR Response

When you start or increase the dose of renin-angiotensin system inhibitors (RASi) including ARBs:

• Check renal function 2-4 weeks after initiation or dose changes 1, 2, 3, 4
• An eGFR decline up to 30% is expected and acceptable 1, 2, 3, 4
• This represents appropriate pharmacologic action, not adverse kidney injury
• The decline typically stabilizes and is associated with long-term preservation of kidney function 1

When to Actually Discontinue or Adjust

Only discontinue olmesartan if:

1. eGFR decline exceeds 30% persistently (recheck after 4 weeks) 1, 2, 3, 4
2. Progressive decline continues beyond the initial dip 5
3. Symptomatic hypotension develops 2, 4
4. Uncontrolled hyperkalemia (>6.0 mEq/L) despite management 2, 3, 4
5. Severe volume depletion or acute illness 5

What to Check First Before Stopping

Before discontinuing olmesartan, systematically evaluate and correct:

• Volume status: Is the patient volume depleted from diuretics or other causes? 5
• Blood pressure: Is MAP <65 mmHg causing hypoperfusion? 5
• Concurrent nephrotoxins: NSAIDs, other medications? 5
• Bilateral renal artery stenosis: Consider if creatinine rose >50% or >1.0 mg/dL 5
• Potassium level: Can often be managed without stopping the ARB 2, 3, 4

Evidence Supporting Continuation

Recent high-quality evidence strongly supports continuing ARBs even with declining kidney function:

• A 2026 nationwide Taiwanese study of 251,853 patients with type 2 diabetes and CKD found that discontinuing RASi when eGFR fell below 45 mL/min/1.73 m² increased risk of: ESRD (HR 2.52), stroke (HR 1.28), heart failure (HR 1.18), and all-cause mortality (HR 1.77) 6

• A 2020 propensity-matched study of 3,909 patients showed that continuing ACE-I/ARB therapy when eGFR dropped below 30 mL/min/1.73 m² was associated with: Lower mortality (HR 0.72) and lower cardiovascular events (HR 0.73) compared to discontinuation 7

• KDIGO 2024 guidelines explicitly recommend continuing ACE-I or ARB even when eGFR falls below 30 mL/min/1.73 m² 2

Managing Your Hypertension Going Forward

If you decide to continue olmesartan (recommended):

1. Recheck creatinine and potassium in 2-4 weeks 1, 2, 3
2. If stable or improved, continue current therapy
3. Monitor every 3-4 months once stable 8, 2
4. Adjust diuretics if volume depleted 5

If you must discontinue (only if meeting criteria above):

• Do not substitute another ARB or ACE inhibitor - they have identical hemodynamic effects 5
• Consider alternative agents: calcium channel blockers, beta-blockers, or thiazide diuretics 9, 1
• Address the underlying cause (volume depletion, hypotension, etc.) first 5
• You can often restart the ARB once precipitating factors are corrected 5

Critical Pitfalls to Avoid

Common mistake: Stopping ARBs prematurely based on an expected eGFR dip, which paradoxically increases long-term risk of kidney failure and cardiovascular events 6, 7.

The 30% rule: A creatinine rise of 0.5 mg/dL from baseline 2.0 mg/dL (25% increase) or 1.0 mg/dL rise from baseline >2.0 mg/dL (also ~30-50%) should trigger evaluation, not automatic discontinuation 5.

Volume depletion is the most common correctable cause of excessive eGFR decline with ARBs - reduce diuretics before stopping the ARB 5.